News

CTCs may aid diagnosis, staging of pancreatic cancer


 

AT THE GASTROINTESTINAL CANCERS SYMPOSIUM

Dr. Rebecca Miksad

The area under a receiver operating characteristic curve was 0.84 (P less than .001), indicating good discrimination between patients with and without metastases.

A subset of seven patients with presumed stage II disease based on preoperative imaging were found to have liver metastases at the time of surgery. In five of them, preoperative blood samples showed at least two CTCs/2 mL, predicting metastatic disease.

"This indicates that CTCs may be potentially useful in predicting preoperative metastasis and directing patients toward more appropriate therapies while having them avoid potentially morbid surgery," Dr. Ankeny commented.

In a final analysis, CTCs were superior to CA 19-9 for discriminating between locoregional disease and metastatic disease, with an area under the receiver operating characteristic curve of 0.87 (P less than .001) vs. 0.69 (P = .06).

Dr. Ankeny disclosed no relevant conflicts of interest. Dr. Miksad disclosed no relevant conflicts of interest.

Pages

Recommended Reading

Despite benefits, ‘bundling’ endoscopy is not norm
MDedge Hematology and Oncology
CT, CEA alone or combined better than nothing to detect colon cancer recurrence
MDedge Hematology and Oncology
Ramucirumab adds to efficacy of chemotherapy in advanced gastric cancer
MDedge Hematology and Oncology
Inflammatory markers associated with IBD colon cancer risk
MDedge Hematology and Oncology
Expanded genetic testing better predicts panitumumab plus chemo response
MDedge Hematology and Oncology
Dual-vaccine therapy prolonged survival in pancreatic cancer
MDedge Hematology and Oncology
Neoadjuvant capecitabine equals infused 5-FU for rectal cancer
MDedge Hematology and Oncology
Aspirin didn’t extend survival in PIK3CA-mutant colorectal cancer
MDedge Hematology and Oncology
Colorectal cancer incidence rising sharply among younger adults
MDedge Hematology and Oncology
MicroRNA screening might reveal pancreatic cancer
MDedge Hematology and Oncology